Predictors of ofloxacin resistance
| Variables | Ofloxacin resistance | Univariate analysis | p-value | Multivariate analysis | p-value | |
| Yes | No | |||||
| Sex | ||||||
| Female | 207 (47.5) | 229 (52.5) | Referent | |||
| Male | 197 (49.7) | 199 (50.3) | 1.095 (0.834.1438) | 0.513 | ||
| Age years | ||||||
| ≤20 | 101 (48.6) | 107 (51.4) | Referent | |||
| 21–40 | 193 (48.9) | 202 (51.1) | 1.012 (0.723–1.416) | 0.944 | ||
| 41–60 | 83 (46.4) | 96 (53.6) | 0.916 (0.614–1.367) | 0.667 | ||
| >60 | 27 (54) | 23 (46) | 1.244 (0.670–2.310) | 0.490 | ||
| Weight kg | ||||||
| <40 | 128 (50.4) | 126 (49.6) | Referent | |||
| ≥40 | 276 (47.8) | 302 (52.2) | 0.900 (0.670–1.209) | 0.482 | ||
| Residence | ||||||
| Rural | 290 (50.9) | 280 (49.1) | Referent | |||
| Urban | 130 (49.6) | 132 (50.4) | 0.891 (0.450–1.032) | 0.452 | ||
| Smear grading | ||||||
| Negative | 22 (44.9) | 27 (55.1) | Referent | |||
| Scanty (1–9 AFB per 100 HPF) | 5 (33.3) | 10 (66.7) | 0.614 (0.183–2.062) | 0.430 | 0.575 (0.168–1.693) | 0.377 |
| +1 (10–99 AFB per 100 HPF) | 132 (53.2) | 116 (46.8) | 1.397 (0.754–2.585) | 0.288 | 1.297 (0.695–2.421) | 0.414 |
| +2 (1–9 AFB per HPF) | 102 (39.5) | 156 (60.5) | 0.802 (0.434–1.485) | 0.484 | 0.772 (0.413–1.443) | 0.418 |
| +3 (>9 AFB per HPF) | 143 (54.6) | 119 (45.4) | 1.475 (0.799–2.723) | 0.214 | 1.378 (0.740–2.566) | 0.313 |
| Previous treatment centre | ||||||
| Public | 166 (43.1) | 219 (56.9) | Referent | Referent | ||
| Private | 193 (55.5) | 155 (44.5) | 1.643 (1.227–2.200) | 0.001 | 1.531 (1.064–2.203) | 0.022 |
| Public/private matrix | 26 (57.8) | 19 (42.2) | 1.805 (0.966–3.373) | 0.064 | 1.668 (0.882–3.154) | 0.115 |
| New patients | 19 (35.2) | 35 (64.8) | 0.716 (0.395–1.297) | 0.271 | 0.487 (0.090–2.634) | 0.403 |
| Previous TB regimen | ||||||
| Category I | 195 (49.9) | 196 (50.1) | Referent | Referent | ||
| Category II | 161 (46.3) | 187 (53.7) | 0.865 (0.648–1.156) | 0.327 | 0.910 (0.676–1.225) | 0.535 |
| New patients | 16 (34.8) | 30 (65.2) | 0.536 (0.283–1.015) | 0.056 | 1.051 (0.218–5.059) | 0.951 |
| Unknown | 32 (68.1) | 15 (31.9) | 2.144 (1.126–4.085) | 0.020 | 2.087 (1.036–4.205) | 0.039 |
| Registration category | ||||||
| New | 20 (36.4) | 35 (63.6) | Referent | Referent | ||
| Failure of previous TB treatment | 182 (46.2) | 212 (53.8) | 1.502 (0.838–2.694) | 0.172 | 0.757(0.130–4.424) | 0.757 |
| Relapse | 27 (45.8) | 32 (54.2) | 1.477 (0.697–3.129) | 0.309 | 0.771 (0.123–4.813) | 0.780 |
| Defaulter of previous TB treatment | 8 (53.3) | 7 (46.7) | 2.000 (0.631–6.339) | 0.239 | 0.850 (0.112–6.465) | 0.876 |
| Unknown outcome of previous episode | 167 (54) | 142 (46) | 2.058 (1.137–3.725) | 0.017 | 0.734 (0.126–4.294) | 0.732 |
| MDR-TB treatment centre | ||||||
| Lady Reading Hospital Peshawar | 230 (48.3) | 246 (51.7) | Referent | |||
| Nishtar Hospital, Multan | 174 (48.9) | 182 (51.1) | 1.023 (0.777–1.346) | 0.874 | ||
Data are presented as n (%) or odds ratios with 95% confidence intervals, unless otherwise stated. AFB: acid fast bacilli; HPF: high power field; TB: tuberculosis; MDR: multidrug-resistant.